Records containing: Schizophrenic Disorders
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-09-19Interest of EMDR (Eye Movement Desensitization and Reprocessing) Psychotherapy in the Management of Schizophrenic Disorders
-
CLINICAL_TRIALS study record update · 2024-02-09Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
-
CLINICAL_TRIALS study record update · 2023-04-03A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
-
CLINICAL_TRIALS study record update · 2019-09-06Study on the Links Between Action and Perception in Schizophrenia, " Have a Good Grasp of the World "
-
CLINICAL_TRIALS study record update · 2016-11-22Study on the Links Between Perception and Action in Schizophrenia, "Upside Down, Give me the Handle"
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2016-09-01Effectiveness of a Physical Activity and Diet Program, Coordinated Between Primary Care and Mental Health, to Modify Cardiovascular Risk Factors in Patients With Schizophrenia or Bipolar Disorder (CapiCor)
-
CLINICAL_TRIALS study record update · 2016-08-15Sodium Butyrate As A Treatment For Improving Cognitive Function In Schizophrenia
-
CLINICAL_TRIALS study record update · 2015-08-17ClinicalTrials.gov study NCT02525315
-
CLINICAL_TRIALS study record update · 2014-06-04Sarcosine (N-methylglycine) Trial for Individuals At Risk for Developing Schizophrenia and Related Disorders
-
CLINICAL_TRIALS study record update · 2014-01-06A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia
-
CLINICAL_TRIALS study record update · 2012-09-12A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting
-
CLINICAL_TRIALS study record update · 2012-03-07The Intervention Involves Education on Nutrition and Physical Activity. Outcomes Evaluate Changes in BMI.
-
CLINICAL_TRIALS study record update · 2012-01-11An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-07-11D-amino Acid Oxidase Inhibition for NMDA Modulation in Schizophrenia
-
CLINICAL_TRIALS study record update · 2011-01-19Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study
-
CLINICAL_TRIALS study record update · 2010-09-17A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
-
CLINICAL_TRIALS study record update · 2007-06-26NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine
-
CLINICAL_TRIALS study record update · 2007-06-22A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2007-06-13The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy
-
CLINICAL_TRIALS study record update · 2006-05-19NMDA Enhancers in the Treatment of Schizophrenia